Innovative HIV Solution ImmunoScience is developing Contre Vir™, a groundbreaking recombinant therapeutic vaccine for HIV and AIDS, with promising pre-clinical and clinical trial results, positioning the company as a potential partner for organizations seeking advanced treatment solutions.

Global Clinical Expansion The company is preparing to initiate Phase I clinical trials in multiple countries including the US, Belgium, Ghana, and Uganda, offering opportunities to collaborate with healthcare providers and research institutions in diverse markets.

Patented Technology With several patents worldwide, ImmunoScience’s proprietary vaccine technology presents a competitive edge, making it an attractive candidate for potential licensing deals or strategic alliances in the biotech sector.

Growing Market Interest High global interest in HIV treatments positions ImmunoScience to attract collaborations with pharmaceutical and biotech companies looking to expand their infectious disease portfolios.

Early Stage Revenue Although revenue is currently modest ($1M–10M), successful clinical development and eventual commercialization of Contre Vir™ could significantly increase sales opportunities through partnerships and licensing with larger industry players.